The feasibility of using pathobiome strains as live biotherapeutic products for human use

Pengfei Jin¹, Xiong Lin², Wenfeng Xu¹, Kangning Li², Xiaoxiao Zhao², Sirui Guo¹, Zinan Zhao¹, Lujie Jiang², Feng Liao², Longgang Chang², Min Wang², Yanmin Liu², Shaolei Huang², Zhangran Chen², Fusui Ji³

¹Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China

²Shenzhen Wedge Microbiology Research Co., Ltd., Shenzhen 518020, China

³Department of Cardiology, Beijing Hospital, National Center of Gerontology, Chinese Academy of Medical Sciences, Beijing 100730, China

Introduction

Pathobiome strains → Transform → Live biotherapeutic products
Section 1: Is pathobiome harmful or beneficial to human health?

Figure 1. The four perspectives for evaluating the goodness or badness of pathobiome strains.
Section 2: The main challenges in utilizing pathobiome strains to develop live biotherapeutic products

Figure 2. The main obstacles in developing pathobiome strains into live biotherapeutic products.
Section 3: Possible future research directions and applications

Functional gene investigation

Microbial Interaction

Basic research

Large scale screening

Recombinant LBP

Bacterial active metabolites

Development form
The evaluation of pathobiome strains should be conducted at the strain level, involving the identification of the functional genes, while considering the impact of ecological niche and drug interactions.

The safety, efficacy, and quality management of LBPs such as pathobiome strains have particular characteristics.

Promising development methods include the recombinant LBP and active metabolites.
“iMeta” is an open-access Wiley partner journal launched by iMeta Science Society consisting of scientists in bioinformatics and metagenomics world-wide. iMeta aims to promote microbiome, and bioinformatics research by publishing research, methods/protocols, and reviews. The goal is to publish high-quality papers (top 10%, IF>20) targeting a broad audience. Unique features include video submission, reproducible analysis, figure polishing, bilingual, and promotion by social media with 500,000 followers. Since 2022 have been published 160 papers and cited > 2300 times. Index by ESCI, Google Scholar, DOAJ and Scopus.

Society: [http://www.imeta.science](http://www.imeta.science)
Publisher: [https://wileyonlinelibrary.com/journal/imeta](https://wileyonlinelibrary.com/journal/imeta)
Submission: [https://wiley.atyponrex.com/journal/IMT2](https://wiley.atyponrex.com/journal/IMT2)